Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?
International Journal of Molecular Sciences · 06.02.2023 · 24 (4) · 3205
DOI: 10.3390/ijms24043205 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.02.2023. Verfasst von Zoe B Mills und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Science, University of Auckland, Auckland 1023, N…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer’s New Zealand, Freemasons New Zealand, Alzheimer’s New Zealand Charitable Trust.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that accounts for more than half of all dementia cases in the elderly. Interestingly, the clinical manifestations of AD disproportionately affect women, comprising two thirds of all AD cases. Although the underlying mechanisms for these sex differences are not fully elucidated, evidence suggests a link between menopause and a higher risk of developing AD, highlighting the critical role of decreased estrogen levels in AD pathogenesis. The focus of this review is to evaluate clinical and observational studies in women, which have investigated the impact of estrogens on cognition or attempted to answer the prevailing question regarding the use of hormone replacement therapy (HRT) as a preventive or therapeutic option for AD. The articles were retrieved through a systematic review of the databases: OVID, SCOPUS, and PubMed (keywords “memory”, “dementia,” “cognition,” “Alzheimer’s disease”, “estrogen”, “estradiol”, “hormone therapy” and “hormone replacement therapy” and by searching reference sections from identified studies and review articles). This review presents the relevant literature available on the topic and discusses the mechanisms, effects, and hypotheses that contribute to the conflicting findings of HRT in the prevention and treatment of age-related cognitive deficits and AD. The literature suggests that estrogens have a clear role in modulating dementia risk, with reliable evidence showing that HRT can have both a beneficial and a deleterious effect. Importantly, recommendation for the use of HRT should consider the age of initiation and baseline characteristics, such as genotype and cardiovascular health, as well as the dosage, formulation, and duration of treatment until the risk factors that modulate the effects of HRT can be more thoroughly investigated or progress in the development of alternative treatments can be made.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Science, University of Auckland, Auckland 1023, New Zealand.
- Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, Ollscoil na Gaillimhe-University of Galway, H91 W5P7 Galway, Ireland.
Förderung
- Alzheimer’s New Zealand
- Freemasons New Zealand
- Alzheimer’s New Zealand Charitable Trust
- Health Research Council of New Zealand
Zitieren
APA
Mills, Z. B., Faull, R. L. M., & Kwakowsky, A. (2023). Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?. International Journal of Molecular Sciences, 24(4), 3205. https://doi.org/10.3390/ijms24043205
Vancouver
Mills ZB, Faull RLM, Kwakowsky A. Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?. International Journal of Molecular Sciences. 2023;24(4):3205. doi:10.3390/ijms24043205
BibTeX
@article{Mills2023,
author = {Mills, Zoe B and Faull, Richard L M and Kwakowsky, Andrea},
title = {Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3205},
doi = {10.3390/ijms24043205}
}
EUVIMED